Clinical Trials Logo

Dementia With Lewy Bodies clinical trials

View clinical trials related to Dementia With Lewy Bodies.

Filter by:

NCT ID: NCT02708186 Completed - Clinical trials for Dementia With Lewy Bodies

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

Start date: March 2016
Phase: Phase 2
Study type: Interventional

This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD).

NCT ID: NCT02702102 Completed - Clinical trials for Dementia With Lewy Bodies

Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies

Start date: December 2015
Phase: Phase 2
Study type: Interventional

This study uses a special type of scan called a positron emission tomography (PET) scan to take pictures of the brain. During the PET scan, a special dye called 11C-PBR28 is injected into the body. 11C-PBR28 sticks to parts of the brain where there is inflammation. The purpose of this study is to see if 11C-PBR28 can detect inflammation in patients with Parkinson's disease dementia or dementia with Lewy bodies. 11C-PBR28 is considered a drug by the Food and Drug Administration. 11C-PBR28 is not a treatment for any disease. Rather, 11C-PBR28 can be used to measure inflammation in the brain.

NCT ID: NCT02669433 Completed - Clinical trials for Dementia With Lewy Bodies

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Start date: January 2016
Phase: Phase 2
Study type: Interventional

This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.

NCT ID: NCT02640339 Completed - Parkinson Disease Clinical Trials

Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease

Start date: February 2016
Phase:
Study type: Observational

- To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime in patients with Parkinson disease. - To establish whether these measures can be used to identify patients with PD in the premotor phase. - To define the rate of progression of retinal abnormalities in PD (both in the motor and premotor stages) for potential use as a clinical outcome measure

NCT ID: NCT02263937 Completed - Clinical trials for Dementia With Lewy Bodies

Deep Brain Stimulation for Patients With Dementia With Lewy Bodies

Start date: January 2014
Phase: N/A
Study type: Interventional

This trial aims to collect pilot data to explore whether bilateral deep brain stimulation (DBS) of the Nucleus Basalis of Meynert (NBM) has beneficial effects on memory and thinking impairments among individuals with Dementia with Lewy Bodies (DLB).

NCT ID: NCT01503944 Completed - Parkinson's Disease Clinical Trials

A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)

Start date: March 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.

NCT ID: NCT01340001 Completed - Clinical trials for Dementia With Lewy Bodies

Effects of Nucleus Basalis of Meynert Stimulation on Cognitive Disorders in Dementia With Lewy Bodies

DEMENSTIM
Start date: October 24, 2012
Phase: N/A
Study type: Interventional

Deep brain stimulation has been developed as a substitute for the classical lesioning methods previously used in stereotactic and functional neurosurgery. Recent, anecdotal cases reports suggested that electrical stimulation of the cholinergic output of the Nucleus Basalis of Meynert (NBM) may improve cognitive performances, especially the memory tasks. The present study aims to assess the effect of bilateral electrical stimulation of the NBM on the mnesic performance [assessed by the sum of the three free recalls of the Free and Cued Selective Recall Reminding Test (FCSRT)] in patients diagnosed with probable, moderate, Dementia with Lewy Bodies.

NCT ID: NCT01023672 Completed - Clinical trials for Dementia With Lewy Bodies

"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"

Start date: November 2009
Phase: Phase 4
Study type: Interventional

This research study is to examine the effects of the study medication Armodafinil in patients with dementia with Lewy bodies (DLB). DLB is associated with memory and other thinking problems, excessive daytime sleepiness, hallucinations, delusions, apathy, and reduced quality of life. One type of medication that could potentially improve daytime sleepiness, memory and thinking skills, hallucinations, delusions, apathy, and quality of life is known as a wake-promoting medication. Armodafinil is a wake-promoting medication that has been developed for treatment of patients with narcolepsy, sleep apnea, and other disorders which cause excessive daytime sleepiness. The drug used in this study is considered investigational, which means it has either not been approved by the Food and Drug Administration (FDA) for routine clinical use or for the use described in this study. However the FDA has allowed the use of this drug/device in this research study. In this study, patients with DLB will receive daily oral Armodafinil tablets, and their response to treatment will be assessed over 12 weeks. This study does not involve any placebo medication, so all patients will receive Armodafinil treatment.

NCT ID: NCT00917709 Completed - Clinical trials for Dementia With Lewy Bodies

Imaging of Vesicular Acetylcholine and Dopamine Transporters in Dementia With Lewy Bodies

IBVM/DATSCAN
Start date: May 2009
Phase: N/A
Study type: Interventional

The general aim of this research project is to determine the relationships between alterations of central cholinergic (ACh) and dopaminergic (DA) systems and neurobehavioral features of dementias with Lewy bodies (DLB). Both clinical and neurochemical data support the view that DLB is not a homogeneous entity and it can be hypothesized that differential alterations of central ACh systems (i.e. anterior vs posterior vs striatal interneurons) in association or not with a DA nigrostriatal dysfunction could partly support the clinical heterogeneity observed in this disease. ACh in vivo imaging has been relatively underutilized to date and to our knowledge only on the postsynaptic side. Furthermore, ACh/DA interactions and their relationships with the symptomatology of DLB and related pathologies (PDD) had never been investigated.

NCT ID: NCT00855686 Completed - Clinical trials for Dementia With Lewy Bodies

Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies

Start date: January 2007
Phase: Phase 4
Study type: Interventional

The purpose of this exploratory study is to determine whether memantine can provide benefits on clinical symptoms in patients with Parkinson's Disease Dementia or Dementia with Lewy Bodies.